Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
Our journey of applying generative AI to advance healthcare
Truveta recently won the SXSW Innovation Award for Artificial Intelligence, which recognized the groundbreaking work we have been doing to apply modern generative AI technology...
Ending the HIV epidemic: Finding new insights with EHR data
In 2019, the US government unveiled the ambitious Ending the HIV Epidemic (EHE) plan, aiming to slash new HIV infections by 90% by 2030. Thanks to advances in antiretroviral...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through March 2024
Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout March 2024 (-32.4%) compared to February 2024. For infants and children, we see...
Trends in the incidence of syphilis among US adults since 2019
Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2019 to December 2023. During the early months of the COVID-19 pandemic,...
Device label expansion using real-world data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion...
Off-label use of drugs and devices in medical practice
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice...
Access to GLP-1 RA anti-obesity medications for Medicare-aged adults
Prior to the new Medicare guidelines going into effect, Truveta Research and Zeke Emanuel, MD, PhD from the University of Pennsylvania, explored the first-time prescribing and...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through February 2024
Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout February 2024 (-20.0%) compared to January 2024. While COVID- and...